<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355575</url>
  </required_header>
  <id_info>
    <org_study_id>2010-021515-17</org_study_id>
    <secondary_id>2010-021515-17</secondary_id>
    <secondary_id>10/H0711/58</secondary_id>
    <secondary_id>45706</secondary_id>
    <nct_id>NCT01355575</nct_id>
  </id_info>
  <brief_title>Rifaximin in Fatty Liver Disease</brief_title>
  <acronym>RiFL</acronym>
  <official_title>RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health Service, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS&#xD;
      Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in&#xD;
      Non-Alcoholic Steatohepatitis (NASH).&#xD;
&#xD;
      AIMS To provide proof-of-concept data on the therapeutic potential of gut flora modification&#xD;
      in NASH OUTCOME MEASURES&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      â€¢ Change in serum ALT from baseline by 25 IU/L or to within normal range after 6 weeks of&#xD;
      Rifaximin therapy&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Change in intrahepatic triglyceride, estimated by in vivo proton magnetic resonance&#xD;
           spectroscopy (1H MRS)&#xD;
&#xD;
        -  Change in hepatic insulin resistance, estimated by the hyperinsulinaemic euglycaemic&#xD;
           clamp&#xD;
&#xD;
        -  Changes to the faecal bacterial microbiome assessed by faecal DNA pyrosequencing and&#xD;
           fluorescent in-situ hybridisation (FISH)&#xD;
&#xD;
        -  Differences in urinary metabolic profiles as assessed by high-resolution proton nuclear&#xD;
           magnetic resonance spectroscopy&#xD;
&#xD;
      POPULATION Patients with biopsy-confirmed non-alcoholic steatohepatitis and persistently&#xD;
      raised serum aminotransferase levels&#xD;
&#xD;
      TREATMENT The non-absorbable antibiotic Rifaximin DURATION This was an open-label study of&#xD;
      Rifaximin (Normix, Alfa Wasserman S.p.A, Bologna, Italy) 400mg twice daily for six weeks&#xD;
      followed by a further six weeks observation period during which patients received standard&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES The primary endpoint was change in ALT after 6 weeks of Rifaximin. Secondary&#xD;
      endpoints were change in hepatic lipid content and insulin sensitivity measured with a&#xD;
      hyperinsulinaemic euglycaemic clamp.&#xD;
&#xD;
      STUDY DESIGN This was an open-label study of Rifaximin (Normix, Alfa Wasserman S.p.A,&#xD;
      Bologna, Italy) 400mg twice daily for six weeks followed by a further six weeks observation&#xD;
      period during which patients received standard care. Compliance with treatment was checked by&#xD;
      collection of empty blister packs. Subjects were asked to provide a structured dietary and&#xD;
      lifestyle history as previously described (Williams HR, Cox IJ, Walker DG, North BV, Patel&#xD;
      VM, Marshall SE, Jewell DP, et al. Characterization of inflammatory bowel disease with&#xD;
      urinary metabolic profiling. Am J Gastroenterol 2009;104:1435-1444). The primary endpoint was&#xD;
      change in ALT after 6 weeks' Rifaximin therapy. Secondary endpoints were change in hepatic&#xD;
      and whole-body insulin sensitivity assessed by the two-stage hyperinsulinaemic euglycaemic&#xD;
      clamp and change in hepatic triglyceride content assessed by proton nuclear magnetic&#xD;
      resonance spectroscopy at 6 weeks from baseline. Serum ALT, biochemistry and anthropometrics&#xD;
      were also measured at 12 weeks to look for longer-term effects. Stool microbiota, urinary&#xD;
      metabolic profile and serum cytokine profile were measured before and after intervention.&#xD;
&#xD;
      PARTICIPANT ENTRY&#xD;
&#xD;
      INCLUSION CRITERIA Male and female patients were eligible for inclusion if aged between 18&#xD;
      and 70 years with non-alcoholic steatohepatitis histologically-proven, as evidenced by the&#xD;
      presence of all of: steatosis, hepatocyte ballooning and lobular inflammation, and scored&#xD;
      according to Kleiner(18) by a single experienced histopathologist (RDG) within the previous&#xD;
      year, with or without mild to moderate fibrosis (stage 0-3/4) and with persistently elevated&#xD;
      alanine aminotransferase (ALT) values on at least two occasions in the three months prior to&#xD;
      recruitment.&#xD;
&#xD;
      EXCLUSION CRITERIA Patients were excluded if there was histological evidence of cirrhosis;&#xD;
      hepatic decompensation; regular alcohol consumption exceeding 14 units/week (16g ethanol/day)&#xD;
      for a woman or 21 units/week (24g ethanol/day) for a man; evidence of viral, autoimmune or&#xD;
      other metabolic liver disease on a chronic liver disease screen; a history of malignancy or&#xD;
      systemic inflammatory conditions; myocardial infarction or cerebrovascular events in the&#xD;
      preceding 6 months; a history of bariatric surgery, blind loop or short bowel; use of any&#xD;
      treatment known or suspected to change bowel flora within 3 months of enrolment; initiation&#xD;
      or major dose change of metformin, thiazolinediones, biguanides, statins, fibrates,&#xD;
      anti-obesity medications or insulin within 3 months of enrolment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary endpoint data review concluded no further patients required.&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>An open label pilot study with two phases (rather than 2 arms). All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>Baseline, 6 weeks (end of treatment) and 12 weeks (6 weeks after end of treatment)</time_frame>
    <description>Alanine aminotransferase (ALT) after 6-weeks of Rifaximin from baseline (end of treatment) and 12 weeks (6 weeks after end of treatment).&#xD;
ALT values reported are the values from 6-weeks Rifaximin treatment compared to baseline, and ALT values from 12 weeks (after 6 weeks of SoC) compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>Baseline and 6 weeks (end of treatment)</time_frame>
    <description>Hepatic and systemic insulin resistance assessed using the hyperinsulinaemic euglycaemic clamp method.&#xD;
Measured in % Suppression of Endogenous Glucose Production (SEGP). Values reported are the value from baseline and value from 6 weeks Rifaximin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Triglyceride Content</measure>
    <time_frame>Baseline and 6 weeks (end of treatment)</time_frame>
    <description>In vivo proton magnetic resonance spectroscopy (1H MRS) to derive a T2-corrected triglyceride to water ratio (hepatic lipid content- intra-hepatocellular lipid (IHCL)).&#xD;
The values reported are the values from baseline and the values from 6 weeks Rifaximin treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>NAFLD</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Rifaximin for 6-weeks followed by 6-week observation period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.</description>
    <arm_group_label>Rifaximin for 6-weeks followed by 6-week observation period</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided written informed consent prior to screening&#xD;
&#xD;
          -  Men and women aged 18-70 years&#xD;
&#xD;
          -  With non-alcoholic steatohepatitis histologically-proven, as evidenced by the presence&#xD;
             of all of: steatosis, hepatocyte ballooning and lobular inflammation, and scored&#xD;
             according to Kleiner(18) by a single experienced histopathologist (RDG) within the&#xD;
             previous year, with or without mild to moderate fibrosis (stage 0-3/4)&#xD;
&#xD;
          -  With persistently elevated alanine aminotransferase (ALT) values on at least two&#xD;
             occasions in the three months prior to recruitment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NAFLD with cirrhosis (fibrosis score 4)&#xD;
&#xD;
          -  Other causes of chronic liver disease&#xD;
&#xD;
               -  Viral hepatitis (HBV, HCV negative)&#xD;
&#xD;
               -  Alcohol intake &gt;14units/week (women) or &gt;21units/week (men)&#xD;
&#xD;
               -  Haemachromatosis (abnormal transferrin saturation, haemochromatosis genotyping)&#xD;
&#xD;
          -  Evidence of hepatic decompensation&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Hepatic encephalopathy&#xD;
&#xD;
               -  Abnormal total bilirubin (except patients with Gilbert's syndrome), albumin,&#xD;
                  prolonged prothrombin time, low platelets)&#xD;
&#xD;
               -  Oesophageal or gastric varices&#xD;
&#xD;
          -  Moderate or severe renal dysfunction (CKD3+, estimated GFR &lt;60ml/min/1.73m2)&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Primary metabolic causes of hepatic steatosis (e.g. familial hypertriglyceridaemia,&#xD;
             abetalipoproteinaemia)&#xD;
&#xD;
          -  Other malignancy&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential unwilling/unable to use&#xD;
             adequate contraceptive methods&#xD;
&#xD;
          -  Systemic inflammatory conditions&#xD;
&#xD;
               -  Arthritis&#xD;
&#xD;
               -  Connective tissue disorders&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
          -  Myocardial infarction within 6 months&#xD;
&#xD;
          -  Stroke within 6 months&#xD;
&#xD;
          -  Bariatric surgery/ blind loop/ short bowel&#xD;
&#xD;
          -  Treatment known/suspected to change gut flora (e.g. systemic antibiotics,&#xD;
             colestyramine, lactulose, polyethylene glycol) within 3 months&#xD;
&#xD;
          -  Treatment with drugs known to cause hepatic steatosis (e.g. corticosteroids, HAART,&#xD;
             amiodarone, high dose oestrogens, tamoxifen) within 3 months&#xD;
&#xD;
          -  Initiation or major dose change of metformin, thiazolidinediones, biguanides, statins,&#xD;
             fibrates, anti-obesity medications or insulin within 3 months of enrolment&#xD;
&#xD;
          -  Patients with allergy to Rifaximin or Rifamycin&#xD;
&#xD;
          -  Patients with a cardiac pacemaker, history of penetrating eye injury, metal foreign&#xD;
             body or any other contra-indication to MRI scanning, as specified in the local MRI&#xD;
             safety checklist&#xD;
&#xD;
          -  Any other clinical, social or psychological issues which, in the opinion of the&#xD;
             investigators may preclude satisfactory completion of the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy FL Cobbold, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark R Thursz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liver Unit, St Mary's Hospital, Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <results_first_submitted>April 14, 2015</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Bacterial endotoxin</keyword>
  <keyword>Hepatic triglyceride</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rifaximin for 6-weeks Then Standard Care</title>
          <description>Rifaximin for 6 weeks in addition to standard care, followed by 6 weeks observation period during which patients receive standard care.&#xD;
Rifaximin: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Combined</title>
          <description>All patients in one group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="32" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Alanine Aminotransferase (ALT) Levels</title>
        <description>Alanine aminotransferase (ALT) after 6-weeks of Rifaximin from baseline (end of treatment) and 12 weeks (6 weeks after end of treatment).&#xD;
ALT values reported are the values from 6-weeks Rifaximin treatment compared to baseline, and ALT values from 12 weeks (after 6 weeks of SoC) compared to baseline.</description>
        <time_frame>Baseline, 6 weeks (end of treatment) and 12 weeks (6 weeks after end of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin for 6-weeks</title>
            <description>Phase 1 Rifaximin: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care for 6-weeks</title>
            <description>Phase 2 The 6-weeks Rifaximin treatment was followed by an observation period for 6-weeks during which patients received standard of care. All patients who had received Rifaximin for 6-weeks then received standard of care for the 6-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Alanine Aminotransferase (ALT) Levels</title>
          <description>Alanine aminotransferase (ALT) after 6-weeks of Rifaximin from baseline (end of treatment) and 12 weeks (6 weeks after end of treatment).&#xD;
ALT values reported are the values from 6-weeks Rifaximin treatment compared to baseline, and ALT values from 12 weeks (after 6 weeks of SoC) compared to baseline.</description>
          <units>iu/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="41" upper_limit="218"/>
                    <measurement group_id="O2" value="83" lower_limit="30" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance</title>
        <description>Hepatic and systemic insulin resistance assessed using the hyperinsulinaemic euglycaemic clamp method.&#xD;
Measured in % Suppression of Endogenous Glucose Production (SEGP). Values reported are the value from baseline and value from 6 weeks Rifaximin treatment.</description>
        <time_frame>Baseline and 6 weeks (end of treatment)</time_frame>
        <population>Data not collected during standard of care.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin Baseline</title>
            <description>Rifaximin baseline</description>
          </group>
          <group group_id="O2">
            <title>Rifaximin After 6-weeks</title>
            <description>Rifaximin: Patients received Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance</title>
          <description>Hepatic and systemic insulin resistance assessed using the hyperinsulinaemic euglycaemic clamp method.&#xD;
Measured in % Suppression of Endogenous Glucose Production (SEGP). Values reported are the value from baseline and value from 6 weeks Rifaximin treatment.</description>
          <population>Data not collected during standard of care.</population>
          <units>% SEGP</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" lower_limit="15.3" upper_limit="51.7"/>
                    <measurement group_id="O2" value="30" lower_limit="10.8" upper_limit="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Triglyceride Content</title>
        <description>In vivo proton magnetic resonance spectroscopy (1H MRS) to derive a T2-corrected triglyceride to water ratio (hepatic lipid content- intra-hepatocellular lipid (IHCL)).&#xD;
The values reported are the values from baseline and the values from 6 weeks Rifaximin treatment.</description>
        <time_frame>Baseline and 6 weeks (end of treatment)</time_frame>
        <population>Data not collected during standard of care.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin Baseline</title>
            <description>Rifaximin baseline</description>
          </group>
          <group group_id="O2">
            <title>Rifaximin After 6-weeks</title>
            <description>Rifaximin: Patients received Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Triglyceride Content</title>
          <description>In vivo proton magnetic resonance spectroscopy (1H MRS) to derive a T2-corrected triglyceride to water ratio (hepatic lipid content- intra-hepatocellular lipid (IHCL)).&#xD;
The values reported are the values from baseline and the values from 6 weeks Rifaximin treatment.</description>
          <population>Data not collected during standard of care.</population>
          <units>% hepatic lipid content</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="2.2" upper_limit="46.2"/>
                    <measurement group_id="O2" value="24.8" lower_limit="1.7" upper_limit="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rifaximin for 6-weeks</title>
          <description>Participants received rifaximin tablet, oral administration, 400mg twice daily for 6-weeks.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care for 6-weeks</title>
          <description>The 6-weeks Rifaximin treatment was followed by an observation period for 6-weeks during which patients received standard of care. All patients who had received Rifaximin for 6-weeks then received standard of care for the 6-week period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stool</sub_title>
                <description>36 hours loose stool which resolved spontaneously and therapy was not discontinued.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jeremy Cobbold</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 1865228756</phone>
      <email>jeremy.cobbold@ndm.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

